hormone human News
-
FPI Explores the Future of Cognitive Healthcare at the 87th China International Medical Equipment Fair (CMEF)
The 87th China International Medical Equipment Fair (CMEF) opened on 14 May at the National Convention and Exhibition Centre (Shanghai). The exhibition is a trendsetter in the global medical device industry and a "top tier" medical event, with brand representatives from more than 20 countries and regions from around the world showcasing sophisticated products spanning the entire industry chain ...
-
EPA Uses Cutting-Edge Technology to Evaluate Chemicals for Human Hormone Impacts
EPA is proposing to use ground-breaking tools developed in the ToxCast program to improve testing for chemicals that have the potential to disrupt hormone function in the human body. EPA uses automated chemical screening technologies to rapidly and simultaneously perform tests on thousands of chemicals and feed the results into computational models to predict hormone-related, endocrine activity. ...
-
Regor announces the first patient dosed in the U.S. in the Phase I clinical trial for RGT-419B, a CDK2/4/6 inhibitor for advanced/metastatic breast cancer
Regor Therapeutics Group, a clinical-stage biotech company focusing on immunology, oncology, and metabolic disorders, announced today that the first patient has been dosed in the Phase I clinical trial of the Company’s next generation targeted inhibitor RGT-419B for the treatment of breast cancer. RGT-419B is a new generation CDK2/4/6, small molecule inhibitor with an optimized kinase ...
-
Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD
Interim Data Anticipated by End of 2022 - Interim Data from PK/PD OraGrowtH212 Trial also Anticipated by End of 2022 - Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced this morning achievement of the 50% randomization milestone for our Phase 2 OraGrowtH210 Trial evaluating orally administered LUM-201 in ...
By Lumos Pharma
-
Lilly Presents Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio® at St. Gallen Virtual Congress 2021
Eli Lilly and Company (NYSE: LLY) today announced patient-reported outcomes (PRO) for the investigational use of Verzenio® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) high risk early breast cancer (EBC). The PRO analysis included patients in both arms ...
-
Regor announces China NMPA approval of the IND for RGT-419B capsule, a CDK2/4/6 inhibitor for advanced/metastatic breast cancer
Regor Therapeutics Group announced that the investigational new drug (IND) application of RGT-419B capsule, a CDK2/4/6 small molecule inhibitor, had been approved by the National Medical Products Administration (NMPA) of China. A Phase I clinical study will be conducted in Chinese patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) ...
-
Regor Therapeutics Announces U.S. FDA Authorization to Conduct Regor`s First-in-Human Clinical Trial with the Next Generation Targeted Inhibitor RGT-419B for Oncology
Regor Therapeutics, a clinical-stage biotech company, announced today authorization from the US Food and Drug Administration (FDA) to proceed with Regor's Phase 1 clinical development plans for RGT-419B. RGT-419B is a new generation CDK2/4/6, small molecule inhibitor with an optimized kinase activity spectrum. It is expected to improve the safety of and combat the resistance to currently ...
-
Juvena Therapeutics Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related Diseases
Juvena Therapeutics, Inc. (“Juvena”), a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins, announced today that it has raised $41 million in an oversubscribed Series A, bringing its total funding to $50 million. The new funding will power the expansion of Juvena’s drug discovery platform and advance the company’s ...
-
EPA to begin testing pesticides for endocrine disruption
EPA has issued the first list of pesticides to be screened for possibly disrupting the endocrine system. Endocrine disruptors are chemicals that interact with and possibly disrupt the hormones produced or secreted by the human or animal endocrine system, which regulates growth, metabolism and reproduction. “Endocrine disruptors can cause lifelong health problems -- especially for children,” ...
-
EPA orders chemical testing for hormone effects
The U.S. Environmental Protection Agency has issued the first test orders for pesticide chemicals to be screened for their potential effects on the endocrine system. Endocrine disruptors are chemicals that interact with and disrupt the hormones produced or secreted by human and animal endocrine systems, which regulate growth, metabolism and reproduction. “After years of delay, EPA is ...
-
Dangerously high levels of endocrine disrupting chemicals found in marine sediments
Endocrine disrupting chemicals (EDCs) can interfere with the hormonal systems of both humans and wildlife. New research quantifying EDCs in marine environments in Greece found concentrations which present significant risks to sediment-dwelling organisms. Reduction and prevention of chemical pollution and subsequent harm to marine ecosystems is a key aim of the EU Marine Strategy Framework ...
-
EPA to Expand Chemicals Testing for Endocrine Disruption
WASHINGTON - The U.S. Environmental Protection Agency (EPA) has identified a list of 134 chemicals that will be screened for their potential to disrupt the endocrine system. Endocrine disruptors are chemicals that interact with and possibly disrupt the hormones produced or secreted by the human or animal endocrine system, which regulates growth, metabolism and reproduction. Administrator Lisa P. ...
-
EPA to expand chemicals testing for endocrine disruption (HQ)
The U.S. Environmental Protection Agency (EPA) has identified a list of 134 chemicals that will be screened for their potential to disrupt the endocrine system. Endocrine disruptors are chemicals that interact with and possibly disrupt the hormones produced or secreted by the human or animal endocrine system, which regulates growth, metabolism and reproduction. Administrator Lisa P. Jackson has ...
-
US drinking water and watersheds widely contaminated by hormone disrupting pesticide, Atrazine
A widely used pesticide known to impact wildlife development and, potentially, human health has contaminated watersheds and drinking water throughout much of the United States, according to a new report released by the Natural Resources Defense Council (NRDC). Banned by the European Union, atrazine is the most commonly detected pesticide in U.S. waters and is a known endocrine disruptor, which ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you